Home | About BIO | Contact Us | Mailing List | Site Map

About BIO

BIO Mission Statement

Biotechnology researchers expand the boundaries of science to benefit mankind by providing better healthcare, enhanced agriculture, and a cleaner and safer environment.

The mission of the Biotechnology Industry Organization (BIO) is to be the champion of biotechnology and the advocate for its member organizations-both large and small.

About BIO

BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,100 members worldwide.

Membership breakdown. Corporate R&D members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. The majority of our members are small companies-88 percent have annual revenues of $25 million or less, reflecting the broader biotechnology industry. BIO also represents academic centers, state and regional biotech associations and service providers to the industry, including financial and consulting firms.

  • R&D-Intensive Companies: 65%. Of those:
    88% have annual revenues under $25 million
    6% have annual revenues between $25 million and $1 billion
    6% have annual revenues over $1 billion
  • Nonprofit/Academic: 18%
  • Service Providers: 11%
  • State/International Affiliate Organizations: 6%

What We Do

Our overarching goal is to advance the industry the world is counting on for new solutions in health, agriculture, manufacturing and energy. BIO's core activities include:

  • Federal and state advocacy. Advocacy to support a climate of innovation is the centerpiece of BIO's mission. BIO's 2007 legislative and regulatory agenda encompasses issues including:
    FDA-Drug safety, increased funding for the Critical Path Initiative and drug reviews, reauthorization of the Prescription Drug User Fee Act and follow-on biologics.
    Prescription drug issues-ensuring reimbursement and patient access to innovative therapies, policies to foster vaccine innovation and pandemic and biodefense preparedness.
    Food & Agriculture-Adventitious presence, animal biotechnology, Biosafety Protocol, international trade.
    Industrial & Environmental-Cellulosic ethanol incentives, farm legislation, state-level incentives.
    Intellectual property-Patent reform, restriction practice reform, research exemption, PTO funding.
    Financial issues-Sarbanes-Oxley reform, tax incentives, expanded SBIR eligibility.

    For complete details on these and other biotechnology issues, visit www.bio.org.

  • Investor and partnering conferences. Understanding the scientific, business and financial relationships among life-sciences companies, BIO hosts partnering conferences in Europe, Asia and the United States. BIO also recognizes the investment needs of the biotech community and hosts regional and national investor conferences. These conferences have grown spectacularly over the last five years: Attendance has more than doubled, and the number of one-on-one meetings has skyrocketed more than 400%. The lineup includes the BIO-Asia Partnering Conference, BIO CEO & Investor Conference, BIO Business Forum at the BIO International Convention and BIO-Europe (Spring and Fall). These events feature expert speakers from the financial and business development communities, as well as presentations from cutting-edge biotechnology companies.

    2006 investor & partnering meeting statistics:
    Attendance: 13,089
    Corporate presentations: 1,394
    One-on-one meetings: 27,125

    Press attendance is welcome at these events. See www.bio.org for information.

  • The BIO International Convention. BIO hosts the industry's signature annual event, attracting more than 20,000 biotechnology executives, scientists, policymakers and journalists from around the world. This year's May 6-9 convention in Boston is expected to be more than double the size of the last BIO convention in that city, held in 2000. The convention features:
    Dozens of sessions covering every biotech trend, policy issue and technological innovation.
    Plenary sessions featuring policymakers, scientists, CEOs and celebrities.
    The world's largest biotechnology exhibit hall.

  • Communications services. BIO is the resource of choice for information on biotechnology and the impact of various policies on our industry. BIO's publications and Web services include:
    BIO News, a members-only newsletter.
    The annual Guide to Biotechnology, a reference guide to biotech products and technology.
    Biotechnology Solutions, a popular brochure on biotech benefits.
    BIO SmartBriefs, a daily e-mailed headline compilation. For complete details on all BIO services, activities and statistics, please visit www.bio.org or contact the Communications Department at 202.962.9200.

Key Facts about the Biotechnology Industry Organization:

  • Founded in 1993
  • Based in Washington, D.C.
  • Chairman: Joshua Boger, PhD, Chairman, President & CEO, Vertex Pharmaceuticals, Inc
  • President & CEO: James Greenwood
  • Represents 1,100 companies and organizations at the federal, state and international levels
  • Represents all biotech applications: health, food & agriculture, industrial & environmental
  • Host of the BIO International Convention, the BIO CEO & Investor Conference and other popular industry events

 

2007 Sponsors

Double Helix Sponsor



Helix Sponsors






Attendees | Exhibitors | Sponsors | myBIO | Business Forum
Site Map | About BIO | Contact Us | Home | Mailing List